This collaboration leverages the expertise of each organization to drive new business opportunities and advance preclinical research.
Able Biolabs supports early-stage research focusing on organoids, small animal models, cell cultures, and more. Led by scientific and medical doctors with a robust scientific team, the company has established expertise in pulmonary, immunology, oncology, and inflammatory disease research.
SRI’s Biosciences division is the largest provider of preclinical services to the National Institutes of Health and offers services spanning pharmacology, toxicology, drug discovery and development, and more. Having advanced more than 200 drugs to clinical trials, SRI has brought 25 to market.
Together, the organizations can offer expanded services, including access to large animal models and GLP-grade studies, reinforcing their combined commitment to developing transformative products that will impact society.
“We look forward to working with SRI to expand our offerings to clients in critical areas,” said Gaurav Mehta, who leads Able Biolabs.
SRI, a renowned nonprofit research institute based in Menlo Park, California, with a long legacy of advancing innovation through multidisciplinary collaboration.
said Kathlynn Brown, head of SRI’s Biosciences division.
To learn more,
